Background-This study evaluates the influence of 3 therapeutic approaches on the incidence of pericarditis and atrial fibrillation (AF) after percutaneous epicardial mapping and ablation for ventricular tachycardia. Methods and Results-Eighty-five consecutive procedures (2006)(2007)(2008)(2009)(2010)(2011) 
C atheter ablation of ventricular tachycardia (VT) is increasingly used for both idiopathic-and scar-related etiologies. 1 In particular, in patients with nonischemic cardiomyopathy, the substrate for VTs is often located intramurally or subepicardially and may require a percutaneous, transpericardial approach. In virtually all patients who undergo an epicardial procedure, pericarditis occurs to a variable extent as a result of local inflammation. 2 This can manifest clinically from mild pericarditis to hemorrhagic pericardial effusion and, rarely, cardiac tamponade. 2 If symptoms occur, patients may be treated with oral anti-inflammatory nonsteroidal and corticosteroid agents. Data on the pharmacokinetic profile of intrapericardially delivered agents have proven favorable, suggesting that targeted local concentrations can be reached with minimal systemic concentrations (therefore, reducing the potential risk of systemic side effects). 2 Intrapericardial corticosteroids and hyaluronic acid have been successfully used to treat recurrent noninfectious pericarditis [3] [4] [5] [6] and to prevent adhesions after open-chest cardiac surgery. 7, 8 The intrapericardial instillation of 2 mg/kg of triamcinolone acetate after epicardial radiofrequency ablation was demonstrated to prevent successfully the occurrence of postprocedure pericarditis and adhesions in porcine animal. 2 Prevention of adhesions may be important, given the potential need to reobtain access to the pericardial space because of recurrence of arrhythmia.
Clinical Perspective on p 676
The occurrence of new-onset atrial fibrillation (AF) after epicardial VT ablation was recently reported to be 19.5% within 7 days. 9 In that study, all patients who developed AF had symptoms of pericarditis. Of note, episodes of AF after epicardial VT ablation may be accompanied by the risk for thromboembolic complications because oral anticoagulation is relatively contraindicated as a result of the risk for pericardial bleeding.
This study was thus designed to evaluate the influence of 3 therapeutic approaches on the incidence of pericarditis and AF after percutaneous epicardial mapping and ablation for VT.
Methods
A total of 85 consecutive procedures in which epicardial mapping or mapping and radiofrequency ablation was performed for VT between 2006 and 2011 were retrospectively reviewed. All patients were treated according to our standard clinical protocol and provided informed consent.
Access to the Pericardial Space
Before the procedure, oral anticoagulation was discontinued. On the day of the procedure, all forms of heparin were withheld. Local anesthesia with conscious sedation was the standard approach for procedural analgesia. Femoral venous and arterial access was obtained, and a quadripolar catheter was positioned at the right ventricular apex. The pericardial space was then entered via a transthoracic percutaneous subxyphoid puncture with a 17-gauge Tuohy needle. Under fluoroscopic guidance, contrast media was injected as the needle was advanced to the pericardium. Once access into the pericardial space was obtained, a guidewire was passed through the needle, over which a 6F introducer sheath was advanced. A 6F pigtail catheter was then introduced into the epicardial space to protect the sheath, and the guidewire was removed. Intravenous heparin was then administered to allow for safe endocardial mapping and ablation.
Mapping and Ablation Procedure
Before epicardial mapping, detailed endocardial mapping was performed to determine the epicardial area of interest to restrict epicardial mapping and minimize potentially painful manipulations. A 3.5 mm irrigated-tip catheter (NaviStar ThermoCool, Biosense Webster Inc, Diamond Bar, CA) was then inserted after replacing the 6F by an 11 cm 8F introducer sheath (Cordis) and was maneuvered within the pericardial space for cardiac mapping and ablation. A 63 cm 8.5F sheath (SLO St-Jude Medical) and subsequently a steerable 71 cm 8.5F sheath (Agilis NxT, medium curl, St-Jude Medical) were used in later procedures. The radiofrequency ablation generator used was the Stockert generator (Biosense-Webster Inc). Epicardial applications were delivered ≤50 W, flow rate 20 mL/min with a temperature limit of 45°C, and delivered for ≤60 seconds each. Fluid was removed after a maximum of 5 radiofrequency applications corresponding to an estimated amount of 100 mL.
Administration of Anti-Inflammatory Agents
The therapeutic approach evolved over time from no steroid therapy to systemic steroids to intrapericardial steroids without overlap between the groups. At the end of the first 17 procedures (20.0%), no steroids were administered. For the subsequent 30 procedures (35.3%), systemic steroids were administered intravenously or orally at a dose of 1 mg per kg per day for 3 consecutive days. The last 38 (44.7%) procedures were followed by complete fluid removal and intrapericardial steroid injection, consisting of triamcinolone acetate (2 mg/kg), which was injected in the pericardial space via a pigtail catheter and left in situ by capping the pigtail. The pigtail was not placed under vacuum. Nonsteroidal anti-inflammatory drugs (NSAIDS), in the form of diclofenac 50 mg every 8 hours, were offered on an asneeded basis to all patients who did not have contraindications.
Postablation Care and Evaluation
Standard postoperative monitoring was performed in all patients, consisting of the first 24 hours in the coronary care unit and at least another 48 hours on the ward. ECGs were obtained immediately after the procedure and subsequently every 12 hours until discharge. Transthoracic echocardiography was performed before pigtail removal and again 12 and 24 hours after pigtail removal. Anticoagulation, where indicated, was restarted after removal of the pigtail catheter.
In patients who developed AF, an early cardioversion at <24 hours of AF duration was favored to avoid the need for anticoagulation. Otherwise, for persistent AF, anticoagulation was initiated ≥24 hours after pigtail removal.
Pericarditis Definition
Pericarditis was defined as typical pericarditic chest pain (pleuritic, improved with sitting upright) with acute pericarditic ECG changes (new widespread ST elevation or PR depression).
Statistical Analysis
Statistical analyses were performed with SPSS version 20 (IBM, Somers, New York, USA). The continuous variables were expressed as number (percentage), mean±SD, or median (interquartile range) where appropriate. χ 2 tests, Fisher exact tests, Student t tests, and Mann-Whitney U tests were performed where applicable. To analyze the effect of steroid treatment on pericarditic chest pain, pericarditic ECG changes, and pericarditis, overall χ 2 tests were performed to compare the 3 treatment groups. Then, 2 one-by-one comparisons were performed, applying the Bonferroni correction for multiple comparisons so that P<0.025 was considered to be statistically significant. For all other tests, P<0.05 was considered to be statistically significant.
Results
Eighty-five epicardial procedures were reviewed, which were performed in 76 patients. Seven patients required a second epicardial procedure (4 of 7 within 2 weeks after the first procedure), and of those 7 patients, 2 underwent a third epicardial procedure 67 and 84 days after the second procedure. The patient characteristics are presented in Table 1 . Only 8 procedures (9.4%) were performed under general anesthesia. Epicardial mapping alone was performed in 29 (34.1%), whereas 56 (65.9%) underwent mapping and ablation. A nonsteerable long sheath (SR0 or SL0) was used in 22 cases (25.9%), whereas an Agilis sheath was used in 42 cases (49.4%). In the mapping only group, epicardial ablation was not performed because of anatomic limitations (coronary arteries or thick fat layer) or because no epicardial ablation target site for VT could be identified.
In the first 17 procedures (20.0%), no steroids were administered. In the subsequent 30 procedures (35.3%), systemic steroids were administered intravenously or orally, whereas in the last 38 procedures (44.7%), intrapericardial steroids were given. On the ward, 62% of patients received NSAIDS for a variety of complaints including chest pain, pain at the pigtail insertion site but also headaches, back pain, and others. The distribution of NSAIDS was the following: 4 of 17 patients (24%) received NSAIDS who had received no steroids, 28 of 30 patients (93%) received NSAIDs who had received systemic steroids, and 21 of 38 patients (55%) received NSAIDs who had received intrapericardial steroids (P<0.001).
Pericarditis occurred after 15.3% of procedures. Pericarditic ECG changes alone, or typical pericarditic chest pain alone, were diagnosed in 20.0% and 21.2%, respectively. There was no age difference between the patients who developed pericarditis and those who did not, with mean ages of 57.6±17.3 versus 58.9±15.1 years, respectively (P=0.474). Clinical chest pain developed within 12 hours of the procedure while the ECG changes occurred within 20 hours at the latest.
The results of the influence of steroid therapy on the incidence of pericarditis are presented in Figure 1 . The incidence of pericarditic chest pain was significantly reduced if patients received intrapericardial steroids (21.1%) compared with no steroids (58.8%; P=0.006). Systemic steroids administration did not significantly reduce the incidence of pericarditic chest pain (43.4% versus 58.8% for patients receiving intravenous or oral steroids or no steroids, respectively, P=0.31). There was no significant difference in the incidence of pericarditic ECG with steroid therapy (36.8%, 30.0%, and 41.2% for intrapericardial, intravenous or oral, or none, respectively). There was a nonsignificant reduced incidence of chest pain with ECG changes with steroids (13.2%, 10.0%, and 29.4% for intrapericardial, intravenous or oral, or none, respectively). Results were similar when only first procedures were analyzed.
There was no statistical difference between mapping alone and mapping with ablation in the incidence of pericarditic chest pain (44.8% versus 32.1%; P=0.249), pericarditic ECG (34.5% versus 35.7%; P=0.910), or both chest pain and ECG changes (24.1% versus 10.7%; P=0.103) as demonstrated in Figure 2 .
The details relating to procedure duration are displayed in Table 2 including procedure duration from time of sheath insertion to sheath removal (median, 4 hours:01 minutes; interquartile range [IQR], 3 hours:20 minutes-4 hours:40 minutes), procedural duration from pericardial puncture to pigtail placement (median, 3 hours:08 minutes; IQR, 2 hours:15 minutes-4 hours:02 minutes), and procedure duration from start of epicardial mapping to pigtail placement (median, 2 hours:00 minutes; IQR, 1 hour:14 minutes-2 hours:40 minutes). There was no difference comparing the above 3 duration times between patients with versus without chest pain, with versus without pericarditic ECG changes, and with versus without both chest pain and pericarditic ECG changes.
A pigtail catheter was left in the pericardial space <3 hours in 8% of patients, whereas 44% patients had the pigtail for ≥24 hours. Patients with a pigtail for ≥24 hours more often had chest pain (51% versus 25%; P=0.012) but less often ECG changes (19% versus 48%, P=0.006) as shown in Table 3 . A total of 13 patients developed a postprocedural pericardial effusion or tamponade with a mean effusion of 12±7 mm by transthoracic echocardiography, observed 18±14 hours after the procedure. The effusion was noted at first echo in 8 of 13 patients, at second echo in 4 patients (20, 20, 20, and 19 hours after procedure), and at third echo in 1 patient (50 hours after procedure but <5 mm).
In 7 (8.3%) patients with no prior history of AF, procedurerelated AF was documented (paroxysmal in 4 and persistent in 3, requiring cardioversion). The median time to new AF was 36 hours (IQR, 19-60 hours). For the persistent cases, 2 underwent rapid cardioversion while the last was anticoagulated for 6 weeks before cardioversion. Patients who developed new-onset AF were older than the patients who did not, with ages of 64.7±7.6 versus 57.2±17.3 years (P=0.016). Patients with a pericarditic ECG tended to be at greater risk of developing AF (16.7% versus 3.6%; P=0.091). There were no complications associated with the episodes of AF. One patient had a recurrence of paroxysmal AF 18 months after resolution of the pericarditis.
The median length of stay in hospital postprocedure was 5 days (IQR, 3-8 days). There was no statistically significant increase in the hospital stay duration because of the incidence of pericarditic chest pain (median 5 days, IQR 3-9 days versus median 5 days, IQR 3-7 days, P=0.75), pericarditic ECG (median 5 days, IQR 3-8 days versus median 4 days, IQR 3-8 days, P=0.98), or of pericarditis (median 5 days, IQR 3-9 days versus median 5 days, IQR 3-8 days, P=0.88).
In 7 patients, repeat epicardial access was required for a total of 9 procedures. In only 1 case, epicardial access to the area of interest could not be reobtained. The patient thus underwent surgical dissection of adhesions and cryoablation. This patient had received oral steroids after his first 2 procedures. Of the 6 patients who underwent unimpeded repeat procedures, 1 had received no steroid, 3 had received oral steroids while 2 had received intrapericardial steroids after the first procedure. Figure 3 demonstrates pericardial adhesions as photographed in the operating room. Interestingly, although an inflammatory process clearly took place, this patient never reported chest pain, and the ECG never demonstrated ECG changes typical of pericarditis.
Complications
In total, 5 patients experienced a bleeding complication that can be further described as follows: 1 case (1.2%) of groin hematoma and 4 cases (4.7%) of moderate to severe pericardial bleeding (>80 mL) occurring acutely in 2 and delayed in 2. For the acute bleeding cases, one occurred after epicardial puncture (without evidence of right ventricular puncture) and resolved within 20 minutes, whereas the second was because of right ventricular puncture. In the first of the delayed bleeding cases, an echo performed because of clinical deterioration with shortness of breath demonstrated tamponade 13 hours after procedure in a patient who had accidentally been administered lowmolecular weight heparin. The second case of delayed bleeding cases occurred in a patient on heparin and dual antiplatelet therapy because of recent coronary artery stenting and was noted 4.75 hours after procedure on an echo performed as a result of low blood pressure and poor diuresis. The bleeding persisted for the following 48 hours. Both were managed with percutaneous drainage. There were no procedure-related deaths.
There were no adverse consequences from the use of intrapericardial triamcinolone more specifically, no infection or myocardial perforation. The patients who underwent redo procedures did so, either as a planned staged approach because of extensive disease and lengthy first ablation procedure or after VT recurrence more than a month after the first ablation procedure.
Discussion
The prophylactic instillation of 2 mg/kg of intrapericardial corticosteroids has been demonstrated to prevent inflammatory adhesions effectively in a porcine model of postprocedural pericarditis after epicardial mapping and ablation. 2 To date, the impact of intrapericardial steroid administration after epicardial mapping and ablation has not been studied in humans. In the present study, it is demonstrated for the first time that the use of intrapericardial steroids portends an important clinical benefit by significantly reducing the incidence of pericarditic chest pain. This is a valuable clinical gain because it is associated with increased patient satisfaction. The clinical benefits of the use of intrapericardial steroids may stem from the mode of delivery, the pharmacokinetics, metabolism of the drug, and the duration of exposure to the drug. Triamcinolone is an intermediate acting, liver metabolized glucocorticoid. Triamcinolone acetate is the more potent type of triamcinolone, being ≈8× as effective as prednisone. The drug thus delivered directly and left in the pericardial space can be absorbed locally. In addition, in this work the drug was left in situ rather than being simply flushed through the epicardial space. Intrapericardial instillation of steroids has also been used in other clinical settings including recurrent idiopathic pericarditis and uremic pericarditis, where studies have consistently demonstrated safety. In the present series, a therapeutic dose of intrapericardial triamcinolone 2 mg/kg was thus chosen. Importantly, there were no adverse consequences from the use of intrapericardial triamcinolone more specifically, no infection or myocardial perforation.
Two recently published studies have reported a widely varying incidence of chest pain after mapping and ablation in the epicardium. 10, 11 The first reported chest pain in almost all patients, 10 whereas the second reported a 21% incidence with 1 of 6 participating centers using systemic steroids routinely and another 1 of 6 participating centers using intrapericardial infusion of steroids routinely. 11 The pathogenesis of the pain in some cases was felt to be related not only to the epicardial mapping and ablation but also to the friction of the pigtail left in the pericardium for continuous drainage.
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In our series, we report an incidence of chest pain of 36.5% (21.2% chest pain only and 15.3% chest pain with ECG changes). Some of the difference in the reported numbers may arise from the difficulty in accurately assessing the quality of the pain retrospectively. In addition, similarly to our approach, the centers included in the above series used a conscious sedation approach, where the analgesic drugs and dosages administered varied and thus provided a varying degree of postprocedural pain control. Also, the type of ablation catheter and sheaths varied from center to center. Furthermore, the use of NSAIDs was not uniform, where in one series it ranged from being left to the discretion of the physician to being prescribed almost routinely for a week. 10 Nevertheless, in the series where steroids were used, 11 including but not only intrapericardial steroids, a lower incidence of chest pain was reported.
With respect to AF, the incidence of 8.3% reported in the present series sits within the range previously quoted in the literature. Already in 1976, the incidence of AF in a cohort of 100 patients with pericarditis was reported to be 5%. 12 An incidence of 19.5% was reported for new-onset AF within 7 days of procedure in a recent series of 41 patients undergoing epicardial VT ablation. 9 In that series, patients developing AF were significantly younger than those without AF, whereas our study demonstrated the opposite. They also described lack of amiodarone therapy as a risk factor for procedurally related new-onset AF. Interestingly, in the data presented here, none of the patients who developed new-onset AF were receiving amiodarone therapy for VT nor did they receive it postprocedurally for AF prevention. On a more concordant note, in their series, all patients with new-onset AF had clinical symptoms of pericarditis, whereas in the present data, there was a trend toward AF occurring more commonly in patients with pericarditic ECG changes. In addition, 85.7% of the patients with new-onset AF in the present series had both mapping and ablation performed. The diverging results between the 2 studies can be in large part explained by the small number of patients developing procedure-related AF in the present series.
Limitations
No randomization was performed; however, the therapeutic approaches in the current study were applied nonselectively in consecutive patients. The findings are, therefore, highly suggestive for an effect of intrapericardial steroids on pericarditic chest pain after epicardial mapping and ablation. The higher incidence of chest pain in patients who had the pigtail ≥24 hours may be explained by the pain resulting from the pigtail itself. When only patients who had the pigtail <24 hours were selected, the effect of steroids on chest pain and ECG changes remained similar (data not shown). Because this is a retrospective study, it is difficult to ascertain from the charts whether patients requested NSAIDs only after the onset of chest pain. The use of NSAIDs however may have had an influence on clinical variables such as pericarditic ECG changes even if the NSAIDs were started after the onset of chest pain. The dose of steroids was unchanged over time and as a result the most effective dose of steroids for the prevention of pericarditic chest pain could not be determined. Although the number of procedures in this study was relatively large, some subgroup analyses were still limited by the sample size. In addition, given that the introduction of the Agilis sheath was contemporary to the introduction of intrapericardial steroids, the relative impact of each variable on the incidence of pericarditis cannot be further determined. However, because the steerable Agilis sheath is assumed to be more traumatic than a nonsteerable sheath, the impact of the intrapericardial steroid on the reduction of clinical pericarditic chest pain may be even underestimated.
Conclusions
There is a high incidence of pericarditic chest pain and of pericarditic ECG after percutaneous epicardial access for VT mapping and ablation. Complaints of pericarditic chest pain are significantly decreased by the administration of intrapericardial steroids but not intravenous or oral steroids. Procedure-related AF is relatively frequent and tends to occur more commonly in patients with pericarditic ECG changes.
